Epirubicin, Cisplatin, and Protracted Venous Infusion of 5-Fluorouracil for Advanced Gastric Carcinoma.
10.3346/jkms.2002.17.3.348
- Author:
Eun Kyung CHO
1
;
Woon Ki LEE
;
Do Yoon LIM
;
Soo Mee BANG
;
Dong Kyun PARK
;
Yeon Ho PARK
;
Oh Sang KWON
;
Duck Joo CHOI
;
Dong Bok SHIN
;
Jae Hoon LEE
;
Tae Hoon LEE
Author Information
1. Department of Internal Medicine, Gachon Medical School, Gil Medical Center, Inchon, Korea. ekcho@ghil.com
- Publication Type:Original Article ; Clinical Trial ; Clinical Trial, Phase II
- Keywords:
Gastrointestinal Neoplasms;
Epirubicin;
Cisplatin;
Fluorouracil;
Infusion Pumps
- MeSH:
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects;
Cisplatin/*administration & dosage/adverse effects;
Epirubicin/*administration & dosage/adverse effects;
Female;
Fluorouracil/*administration & dosage/adverse effects;
Humans;
Infusion Pumps;
Infusions, Intravenous;
Male;
Middle Aged;
Stomach Neoplasms/*drug therapy/mortality/secondary;
Survival Analysis
- From:Journal of Korean Medical Science
2002;17(3):348-352
- CountryRepublic of Korea
- Language:English
-
Abstract:
To evaluate the activity and safety of a combination chemotherapy with epirubicin, cisplatin, and a protracted venous infusion of 5-fluorouracil (ECF) in unresectable or metastatic gastric cancer, a phase II study was performed. Thirty-five chemotherapy-naive patients were given ECF. Epirubicin (50 mg/m2 intravenous, IV) and cisplatin (60 mg/m2 IV) were administered every three weeks during a continuous intravenous infusion of 5-fluorouracil (250 mg/m2 /day) using infusion pump. One complete response and 19 partial responses (response rate=62%) were achieved. Eight patients remained stable, whereas in four patients the disease progressed. The median duration of response was 22 weeks (95% confidence interval, 18-27 weeks). The median survival for all patients was 10 months (95% confidence interval, 6-14 months), with a 1-yr survival rate of 40%. A total of 184 cycles of chemotherapy were administered. Grade 3 or 4 emesis occurred in 3%, mucositis in 2%, anemia in 10%, and leukopenia in 3% of the cycles. Central venous catheter complications that required line removal occurred in 37% (n=13) of the patients. No patient died of toxicity. Overall, the ECF regimen showed high anti-tumor activity with a tolerable toxicity pattern.
